2019 M. Irene Ferrer Awardee, Columbia University
Dr. Jennifer Amengual’s research goals are focused on developing targeted therapies for the treatment of lymphoma. Primary mediastinal b-cell lymphoma (PMBCL) is a distinct entity which harbors both epigenetic and immune derangements driving lymphogenesis. It is a disease that predominantly affects women in their third and fourth decades of life. Dr. Amengual hopes to understand how epigenetic modulation affects the expression of key determinants and drivers of PMBCL and immune function and to determine if combined epigenetic modulation and immune checkpoint inhibition is synergistic in PMBCL.